Novocure announced today that the first patients have enrolled in the EF-21 Study, a prospective randomized clinical study of NovoTTF™ Therapy for patients with brain metastases from non-small cell lung carcinoma (NSCLC) cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System.
"The EF-21 Study builds on extensive preclinical research on the effect of NovoTTF Therapy in preventing cancer from metastasizing to the brain in animal models," said Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development. "The study also builds on a prior clinical study evaluating the efficacy of the therapy as a treatment for primary NSCLC tumors."
The first patients have been enrolled by Na Homolce Hospital in Prague, Czech Republic and the Medical University Hospital in Vienna, Austria. The EF-21 Study is now open to enrollment at four centers in Austria, Czech Republic, Israel and Italy, and will include centers in Sweden, Poland and Spain.
"Novocure is committed to performing clinical trials across a broad range of solid tumor cancers," said Asaf Danziger, Novocure's Chief Executive Officer. "We look forward to working with our EF-21 Study investigators to evaluate NovoTTF Therapy as a treatment for patients with brain tumors from metastatic lung cancer."
Exposure to polycyclic aromatic hydrocarbons may increase cancer risk